Neoplasms

Digestive System Diseases

All Conditions

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Antineoplastic Agents

All Drugs and Chemicals

Oxaliplatin

Apatinib

Capecitabine

Protein Kinase Inhibitors

Enzyme Inhibitors

Apatinib Mesylate Tablets 500 mg P.O.d1-21 and XELOX (oxaliplatin 130mg/㎡ i.v. d1, capecitabine 1000mg P.O. d1-d14)

Every 3-week time is a cycle until PD or intolerance of drug toxicity occurs.

Apatinib and XELOX combined treatment group

Shoucheng Ma, Master

Da Zhao, Bachelor

This study makes an observation over the objective response rate of Apatinib and XELOX combination regimen in the first-line treatment of metastatic colorectal cancer. All the participants will receive the treatment of Apatinib and XELOX combination regimen.

XELOX chemotherapy is an effective therapy for metastatic colorectal cancer as first-line treatment.

Apatinib is a small-molecule tyrosine kinase inhibitor (TKI) that highly selectively binds to and strongly inhibits vascular endothelial growth factor receptor 2 (VEGFR-2), with a decrease in VEGF-mediated endothelial cell migration, proliferation, and tumor microvascular density. A phase II trail of Apatinib has been demonstrated that Apatinib is safe to treat the metastatic colorectal cancer and the disease control rate can reach 50%.

Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients

A Phase II Clinical Trial Study on Apatinib and XELOX Combination Regimen in the First-line Treatment of End-stage Colorectal Cancer Patients

ORR=complete response (CR) + partial response (PR) .And expected ORR is 0.55.

time from randomization to documented progressive disease or death due to any cause, whichever occurs first

Shoucheng Ma

director of cancer center

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients	NCT02829385	Colorectal Neop...	Apatinib and XE...	18 Years - 75 Years	LanZhou University
Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients	NCT02829385	Colorectal Neop...	Apatinib and XE...	18 Years - 75 Years	LanZhou University

Spots Global Cancer Trial Database for apatinib and xelox combined treatment group